within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AE10_Darunavir;

model Darunavir
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.37,
    Cl = 3.4722222222222224e-06,
    adminDuration = 600,
    adminMass = 800 / 1000000,
    adminCount = 1,
    Vd = 0.00155,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.007333333333333333,
    Tlag = 12.0,
    Vdp = 0.0009,
    k12 = 5.1666666666666675e-06,
    k21 = 5.1666666666666675e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Darunavir</td></tr><tr><td>ATC code:</td><td>J05AE10</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>800</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.55</td><td>L</td></tr>
    <tr><td>clearance:</td><td>12.5</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Darunavir is a protease inhibitor used as part of combination antiretroviral therapy for the treatment of human immunodeficiency virus (HIV-1) infection. It is approved for use in adults and children over 3 years old, often co-administered with ritonavir or cobicistat to enhance its pharmacokinetic properties.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy HIV-infected adults after oral administration of darunavir (boosted with ritonavir 100 mg) 800 mg once daily.</p><h4>References</h4><ol><li><p>Cojutti, PG, et al., &amp; Pea, F (2020). Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6. <i>Clinical pharmacokinetics</i> 59(10) 1251–1260. DOI:<a href=\"https://doi.org/10.1007/s40262-020-00933-8\">10.1007/s40262-020-00933-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32856282/\">https://pubmed.ncbi.nlm.nih.gov/32856282</a></p></li><li><p>Dickinson, L, et al., &amp; Boffito, M (2020). Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>The Journal of antimicrobial chemotherapy</i> 75(3) 628–639. DOI:<a href=\"https://doi.org/10.1093/jac/dkz479\">10.1093/jac/dkz479</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31754703/\">https://pubmed.ncbi.nlm.nih.gov/31754703</a></p></li><li><p>Dickinson, L, et al., &amp; Siccardi, M (2016). Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. <i>The Journal of antimicrobial chemotherapy</i> 71(4) 1041–1045. DOI:<a href=\"https://doi.org/10.1093/jac/dkv439\">10.1093/jac/dkv439</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26712906/\">https://pubmed.ncbi.nlm.nih.gov/26712906</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J05AE10 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Darunavir;
